U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. About Science & Research at FDA
  4. FDA Grand Rounds
  5. FDA Grand Rounds: Microphysiological Systems as Novel Disease Models and Drug Development Tools - 03/09/2023
  1. FDA Grand Rounds

Webcast | Virtual

Event Title
FDA Grand Rounds: Microphysiological Systems as Novel Disease Models and Drug Development Tools
March 9, 2023

Date:
March 9, 2023
Time:
12:00 p.m. - 1:00 p.m. ET
Image
FDA Grand Rounds - March 9, 2023: Microphysiological Systems as Novel Disease Models and Drug Development Tools, Thursday, March 9, 2023, 12:00 p.m. - 1:00 p.m. EST

About the Speakers

Dayton Petibone, PhD
Division of Genetic and Molecular Toxicology 
National Center for Toxicological Research
U. S. Food and Drug Administration

Dayton Petibone, PhD, is a Research Biologist in the Division of Genetic and Molecular Toxicology at FDA’s National Center for Toxicological Research (NCTR). Dr. Petibone, in collaboration Scientists from the FDA’s Center for Biologics Evaluation and Review, is currently developing in vitro models of ZIKV infection and transmission. Dr. Petibone received his PhD in Applied Bioscience from the University of Arkansas at Little Rock.

Qiang Shi, PhD
Division of Systems Biology
National Center for Toxicological Research
U.S. Food and Drug Administration

Dr. Qiang Shi obtained a PhD in pharmacology from Zhejiang University in China. He completed his postdoctoral training in drug induced liver injury (DILI) at FDA’s National Center for Toxicological Research (NCTR) between 2007 and 2010, when he was then converted to a visiting scientist. Dr. Shi’s main research focus is mechanisms, biomarkers, and models for DILI.

About the Presentation

The Zika virus (ZIKV) may be sexually transmitted and can result in birth defects or fetal loss. The presentation is an evaluation of testicular organoids for use as an in vitro model of ZIKV infection. Once developed, this model might be useful for evaluating potential vaccines or treatments for ZIKV infection in the male reproductive system.

Liver microphysiological systems (MPS) are novel cell culture approaches aimed at maintaining in vitro the main physiological characteristics that these cells present in the liver of live laboratory animals or humans. During this presentation, major commercial liver MPS will be introduced, focusing on how they work and the pros and cons of each platform. The challenges in using liver MPS to help reduce or refine animal tests will also be discussed.

Learning Objectives

  1. Describe the ways Zika virus is transmitted among the human population and the negative outcomes associated with Zika virus infection.
  2. Discuss how in vitro testicular organoid models can be used as a model of Zika virus infection.
  3. Explain the definition of liver microphysiological systems.
  4. Describe how the major commercial liver microphysiological systems work.
  5. Discuss the hopes and challenges of using liver microphysiological systems to aid drug discovery and development.

Webcast Recording

FDA employees MUST register in BOTH the following: 

https://fda.zoomgov.com/rec/share/VS4rWG80cnry7787R09TPDJPRNsztTJ2j21ST3v3lMOGT5FPE2zbB_cSxge5tqBj.Mv0it6G2JrrCjoXu

Event Materials  

Activity Outline FDA Grand Rounds: March 9, 2023

Back to Top